DD Dec 2019 77.500 put

OPR - OPR Delayed Price. Currency in USD
7.25
0.00 (0.00%)
As of 2:28PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close7.25
Open7.25
Bid5.80
Ask6.05
Strike77.50
Expire Date2019-12-20
Day's Range7.25 - 7.25
Contract RangeN/A
Volume41
Open InterestN/A
  • Moody's

    DuPont de Nemours, Inc. -- Moody's announces completion of a periodic review of ratings of DuPont de Nemours, Inc.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of DuPont de Nemours, Inc. New York, November 11, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of DuPont de Nemours, Inc. and other ratings that are associated with the same analytical unit. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • Thomson Reuters StreetEvents

    Edited Transcript of DD.N earnings conference call or presentation 31-Oct-19 12:00pm GMT

    Q3 2019 Dupont De Nemours Inc Earnings Call

  • 7 Stocks Poised to Rise as Market Enters Best Stretch in 8 Decades
    Investopedia

    7 Stocks Poised to Rise as Market Enters Best Stretch in 8 Decades

    The November to January period historically offers the strongest stock market returns, and these stocks may be poised to ride that seasonal pattern.

  • Chemical Stock Earnings Due on Nov 7: APD, ESI, TROX & ICL
    Zacks

    Chemical Stock Earnings Due on Nov 7: APD, ESI, TROX & ICL

    Let's take a look at how these chemical companies are poised ahead of their earnings release.

  • Should You Be Worried About DuPont de Nemours, Inc.'s (NYSE:DD) 7.4% Return On Equity?
    Simply Wall St.

    Should You Be Worried About DuPont de Nemours, Inc.'s (NYSE:DD) 7.4% Return On Equity?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • GuruFocus.com

    US Indexes Close Higher Friday and for the Week

    S&P; 500 up 22.19% for the year Continue reading...

  • Barrons.com

    It’s Been a Tough Year in Agriculture. Farm-Supply Stocks Take Different Paths.

    Two companies that supply farmers— (CTVA) and (FMC)—are on different paths as investors assess their quarterly results. The stock (ticker: CTVA) fell 4% Thursday, worse than the 0.5% decline of the Dow Jones Industrial Average. For Corteva, “we had previously thought there was a possibility that domestic corn yields might be significantly impaired in 2019 due to adverse weather conditions that led to a very late planting season,” wrote Zekauskas in a Friday research report.

  • Barrons.com

    DuPont Stock ‘Is Too Cheap’ and Has Catalysts

    DuPont stock is up a second straight day after reporting third-quarter numbers. Some on Wall Street see opportunity in the company’s nutrition business is sold or spun off.

  • DuPont Rises 4%
    Investing.com

    DuPont Rises 4%

    Investing.com - DuPont (NYSE:DD) rose by 4.05% to trade at $68.57 by 10:31 (14:31 GMT) on Friday on the NYSE exchange.

  • GuruFocus.com

    US Indexes Close Lower Thursday

    S&P; 500 up 2% for October Continue reading...

  • MarketWatch

    DuPont says its nutrition & biosciences business got a boost from plant-based meat demand

    One of the hottest food trends featured in the earnings of specialty chemicals company DuPont de Nemours Inc. on Thursday. The company said it's nutrition & biosciences (N&B) business saw a boost in food and beverage volumes driven by gains in specialty proteins from growing demand for plant-based meats. On the company's earnings call with analysts, Chief Operating Officer Marc Doyle said the company's plant-based meat business is "relatively small today," but that it is expected to grow in the double digits. Alternative meat has become a big business in the U.S., as companies' like Beyond Meat Inc. and Impossible Meat are introducing their products at more restaurants and fast-food outlets, as well as on grocery shelves. DuPont's N&B business is just one of four business segments, along with electronics & imaging, transportation & industrial and safety & construction. DuPont shares were up 1% Thursday, but have fallen 13% in 2019, while the S&P 500 has gained 21%.

  • DuPont (DD) Beats on Q3 Earnings & Sales, Narrows EPS View
    Zacks

    DuPont (DD) Beats on Q3 Earnings & Sales, Narrows EPS View

    DuPont (DD) gains from higher pricing, portfolio actions and cost control amid a challenging macroeconomic environment in Q3.

  • Barrons.com

    DuPont’s Earnings Beat the Street. They Also Point to a Stronger World Economy.

    DuPont’s results beat the Wall Street consensus by a couple of pennies. The better news is that some DuPont businesses, an indicator of the outlook for the global economy, are showing early signs of improvement.

  • DuPont's (DD) Q3 Earnings and Sales Beat Estimates
    Zacks

    DuPont's (DD) Q3 Earnings and Sales Beat Estimates

    DuPont's (DD) Q3 adjusted earnings of 96 cents per share surpassed the Zacks Consensus Estimate of 95 cents.

  • Barrons.com

    The S&P 500 Will Have to Fight for Another Record Because Trade Worries Are Back

    Wall Street is looking at a shaky start for Thursday, thanks to fresh rumblings on the trade front that may take the shine off upbeat results from Apple and Facebook.

  • Reuters

    UPDATE 2-DuPont profit edges past estimates on higher product prices, lower costs

    Industrial materials maker DuPont's quarterly profit edged past analysts' estimates on Thursday and sales in China improved for the second quarter in a row, sending shares up 3.5%. Sales in China, which accounted for about 15% of total revenue, were driven by higher demand for a film used in newer smartphones and helped offset weakness in its electronic and automotive sectors. A protracted trade dispute between the United States and China as well as fears of a global economic slowdown have been weighing on DuPont and rivals Germany's BASF and Dow inc.

  • MarketWatch

    DuPont reiterates sales view as profit drops 26%

    DuPont largely reiterated guidance after it reported a 26% decline in third-quarter net income to $372 million, or 50 cents a share, as sales fell 5% to $5.4 billion and organic sales slipped 2%. The company said its adjusted EPS was 96 cents. Analysts polled by FactSet expected earnings of 94 cents a share on sales of $5.4 billion. DuPont said it reiterates full-year guidance for organic revenue of slightly down versus prior year and narrows the guidance range for pro forma adjusted EPS to $3.77 to $3.82 from $3.75 to $3.85.

  • DuPont Reports Third Quarter Results
    PR Newswire

    DuPont Reports Third Quarter Results

    WILMINGTON, Del. , Oct. 31, 2019 /PRNewswire/ -- 3Q19 GAAP EPS from continuing operations of $0.49 ; Adjusted EPS of $0.96 , up 2 percent versus prior year 3Q19 GAAP Income from continuing operations of ...

  • DuPont Earnings Beat, Revenue Misses In Q3
    Investing.com

    DuPont Earnings Beat, Revenue Misses In Q3

    Investing.com - DuPont reported third quarter earnings that beat analysts' expectations on Thursday and revenue that fell short of forecasts.

  • GuruFocus.com

    Why High-Yielding Dow Inc. Could Outperform in a Market Downturn

    Dow's high dividend yield and negative beta could produce strong out-performance if the market falls Continue reading...

  • DuPont Announces 2030 Sustainability Goals
    PR Newswire

    DuPont Announces 2030 Sustainability Goals

    WILMINGTON, Del., Oct. 30, 2019 /PRNewswire/ -- DuPont (DD) today announced its 2030 Sustainability Goals, underscoring the importance of sustainability in fulfilling its purpose of delivering essential innovations to help societies thrive. The goals also draw inspiration from the United Nations Sustainable Development Goals (SDGs) to identify the world's most important problems that need to be solved. "DuPont's 2030 goals set forth our priorities and align to the sustainability challenges that offer the greatest opportunity to deliver business value, increase resiliency across our value chains and enable people and societies to thrive," said Marc Doyle, Chief Executive Officer for DuPont.

  • Barrons.com

    DuPont Earnings Are Coming. Here’s What To Expect.

    It’s been a tough year for the chemical giant. DuPont reports third-quarter numbers before the market opens for trading on Thursday. Those results will determine whether the stock can claw back some lost ground.

  • DuPont (DD) Gears Up for Q3 Earnings: What's in the Cards?
    Zacks

    DuPont (DD) Gears Up for Q3 Earnings: What's in the Cards?

    Soft demand is expected to have impacted DuPont's (DD) organic sales in the third quarter.

  • 3 Buy-Rated Stocks You May Never Heard Of
    TipRanks

    3 Buy-Rated Stocks You May Never Heard Of

    Growth investors are constantly looking for the next massive gainer. We mean the stocks that not only have a proven track record for growth but also exhibit strong long-term growth prospects that could yield high rewards in the years to come.While it’s often tempting to turn to more mainstream names like Apple, these better-known stocks don’t always offer the most upside from the current share price. In this case, stocks that have slipped away from investors' radars can represent more compelling investments as their biggest gains could still be on the way.That being said, finding these under-the-radar names that are poised to skyrocket can seem like a daunting task to even the most seasoned investors. Luckily, TipRanks’ Smart Score tool makes it a little easier. Using the tool, we were able to pinpoint 3 lesser-known stocks primed to take off.Teleflex (TFX)Teleflex develops and manufactures single-use medical devices such as products used for anesthesia, fluid management as well as hand-held instruments. While experiencing a rocky last few months, several analysts believe TFX is well positioned to deliver high returns.Part of the medical device company’s appeal lies with its UroLift product. The system, which is a minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), has been approved by the FDA and has been used to treat over 100,000 men globally. With TFX placing the available market opportunity in the U.S. at $6 billion due to the fact that 1.5 million men with BPH have abandoned treatment, UroLift is expected to continue to fuel significant revenue.Additionally, its new MANTA vascular closure device looks especially promising. With the full launch of MANTA slated for 2020, Jeffries analyst Raj Denhoy believes TFX has a “best-in-class reported and organic top-line growth profile relative to peers”. He added, “With TFX now positioned as one of the better positioned mid-cap hospital supply providers, the company is now increasingly attractive to larger diversified medtech peers."As a result, the five-star analyst reiterated a Buy rating and $415 price target on TFX stock. Based on Denhoy's price target, shares could surge 29% over the next twelve months. (To watch Denhoy’s track record, click here)Similarly, the rest of the Street takes a bullish approach when it comes to TFX. 6 Buy ratings and 1 Hold give the stock a ‘Strong Buy’ analyst consensus. Its $397 average price target suggests 24% upside potential. (See Teleflex stock analysis on TipRanks)DuPont de Nemours (DD)It’s no question that the chemical company has received its fair share of negative attention in recent years. Nonetheless, DuPont shares could get a lift thanks to its focus on active portfolio management.Management believes synergies resulting from recent M&A activity could drive substantial gains in terms of revenue. On October 3, DD announced that it had agreed to acquire the Memcor business from Evoqua Water Technologies Corporation. As a result of the deal, Dupont will get access to Evoqua’s ultrafiltration and membrane biofiltration technologies. This acquisition comes on the heels of an earlier agreement with BASF to acquire the ultrafiltration membrane segment of the business.Not to mention the company should see cash flow improve following the sale of its Compound Semiconductor Solutions business.Bearing this in mind, Morgan Stanley analyst Vincent Andrews sees DD’s potential 12-month gain falling at 28%, as he reiterates an Overweight rating and $85 price target. (To watch Andrews’ track record, click here)“We remain of the view that: 1) A ~$100 per share bull case exists should the company achieve max strategic value creation with its four generally unrelated segments; 2) The current share price does not price in any strategic value creation, but rather a typical conglomerate discount,” Andrews noted.Wall Street anchor a bullish perspective on the chemicals maker, as TipRanks analytics showcase DD as a Moderate Buy. Based on 12 analysts polled by TipRanks in the last 3 months, 8 rate DD a "buy," while 4 say "hold." The 12-month average price target stands at $80.82, marking a nearly 20% upside from where the stock is currently trading. (See DuPont stock analysis on TipRanks)Corteva (CTVA)Originally the agricultural component of DowDuPont, Corteva is now a separate company specializing in agricultural chemicals and seeds. With shares dipping 8% in the last month, Deutsche Bank’s David Begleiter argues that the drop represents a unique buying opportunity.The company has recently added a new bundling program called Corteva Cash, with the product already proving to be successful. The bundling program gives seed purchasers a cash credit that can be used to buy pesticides from Corteva. As a result, there has been an uptick in purchases of CTVA pesticides from farmers.In addition to Corteva Cash, the company has placed a significant focus on improving its productivity levels. CTVA recently announced the launch of its “Execute to Win” productivity program to fuel $500 million of EBITDA over the next five years. A new ERP platform is also being put into place in order to address excess costs from its three disparate IT systems including DuPont Crop Protection, Pioneer and Dow Agrosciences, as well as simplify business operations.All of this lends itself to Begleiter’s conclusion that CTVA’s 2x EBITDA discount to FMC Corporation is “unwarranted”. “With double-digit EBITDA growth over the next 3-4 years largely in its own control (due to its substantial cost synergies and productivity initiatives) and valuation compelling versus its closest peer, we reiterate our Buy rating,” he commented. Along with his Buy rating, the five-star analyst set a $35 price target, indicating 37% upside potential. (To watch Begleiter’s track record, click here)Overall, the agricultural chemical maker has had 3 bullish analysts in its corner over the last three months, along with 2 neutral analysts. Importantly, the 12-month average price target of $33,40 showcases 25% in upside potential for the stock.